Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | EVP, Head of R&D | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Ending reported balance
After 2026-09-01 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 7,500 · Balance 11,500 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 6,249 · Balance 17,749 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 9,375 · Balance 27,124 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Row 4 · 2026-09-01 · Sale · Disposed 2,600 · Balance 24,524 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.50 to $105.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-09-01 · Sale · Disposed 7,215 · Balance 17,309 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.53 to $106.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2026-09-01 · Sale · Disposed 13,309 · Balance 4,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.53 to $107.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.88 · Expires 2034-01-23 | Direct | 56,776 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Exercise / conversion · Disposed 7,500 · Balance 56,776 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F5: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.77 · Expires 2034-05-22 | Direct | 41,676 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 6,249 · Balance 41,676 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F6: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.07 · Expires 2035-02-03 | Direct | 87,500 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 9,375 · Balance 87,500 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F7: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.50 to $105.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.53 to $106.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.53 to $107.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F6: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F7: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · derivative · entry 9 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 9,375 shares Expires 2035-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,249 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · derivative · entry 8 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,676 Underlying: Common Stock · 6,249 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · derivative · entry 7 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,776 Underlying: Common Stock · 7,500 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 13,309 | $106.74 | $1,420,602.66 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 6 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.53 to $107.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 7,215 | $106.25 | $766,593.75 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 5 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,309 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.53 to $106.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,600 | $105.19 | $273,494.00 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 4 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,524 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.50 to $105.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 9,375 | $22.07 | $206,906.25 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 3 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 6,249 | $21.77 | $136,040.73 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 2 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 7,500 | $17.88 | $134,100.00 |
DisclosureSEC source: 0001992260-26-000009 · ownership.xml · nonDerivative · entry 1 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · derivative · entry 11 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,875 Underlying: Common Stock · 9,375 shares Expires 2035-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F8 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,249 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · derivative · entry 10 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,925 Underlying: Common Stock · 6,249 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,908 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · derivative · entry 9 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,276 Underlying: Common Stock · 6,908 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,998 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · derivative · entry 8 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,998 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 4,159 | $91.37 | $380,007.83 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 7 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.17 to $91.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 16,943 | $90.72 | $1,537,068.96 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 6 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,159 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.17 to $91.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 5,428 | $89.72 | $487,000.16 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 5 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,102 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.17 to $90.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 9,375 | $22.07 | $206,906.25 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 4 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 6,249 | $21.77 | $136,040.73 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 3 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 6,908 | $17.88 | $123,515.04 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 2 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 3,998 | $8.44 | $33,743.12 |
DisclosureSEC source: 0001992260-26-000006 · ownership.xml · nonDerivative · entry 1 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · derivative · entry 9 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,250 Underlying: Common Stock · 12,500 shares Expires 2035-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,332 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · derivative · entry 8 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,174 Underlying: Common Stock · 8,332 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F4 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · derivative · entry 7 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,184 Underlying: Common Stock · 5,000 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,998 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · derivative · entry 6 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,998 Underlying: Common Stock · 7,998 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 33,830 | $81.48 | $2,756,468.40 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · nonDerivative · entry 5 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 12,500 | $22.07 | $275,875.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · nonDerivative · entry 4 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 8,332 | $21.77 | $181,387.64 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · nonDerivative · entry 3 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 5,000 | $17.88 | $89,400.00 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · nonDerivative · entry 2 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 7,998 | $8.44 | $67,503.12 |
DisclosureSEC source: 0001992260-26-000004 · ownership.xml · nonDerivative · entry 1 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:40 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $52.46 | $0.00 |
DisclosureSEC source: 0001992260-26-000002 · ownership.xml · derivative · entry 1 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,250 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · derivative · entry 14 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,750 Underlying: Common Stock · 31,250 shares Expires 2035-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F8 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,494 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · derivative · entry 13 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,506 Underlying: Common Stock · 37,494 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,287 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · derivative · entry 12 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,184 Underlying: Common Stock · 40,287 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 109,031 | $38.14 | $4,158,442.34 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 9 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 31,250 | $22.07 | $689,687.50 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 8 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 37,494 | $21.77 | $816,244.38 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 7 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 40,287 | $17.88 | $720,331.56 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 6 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,529 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · derivative · entry 11 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,471 Underlying: Common Stock · 3,529 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 83,978 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · derivative · entry 10 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,996 Underlying: Common Stock · 83,978 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 18,576 | $37.72 | $700,686.72 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 5 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.48 to $38.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 42,765 | $37.04 | $1,584,015.60 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 4 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,576 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.48 to $37.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 26,166 | $35.80 | $936,742.80 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 3 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,341 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 3,529 | $17.88 | $63,098.52 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 2 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 02:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 83,978 | $8.44 | $708,774.32 |
DisclosureSEC source: 0001992260-25-000008 · ownership.xml · nonDerivative · entry 1 Randhawa Simrat · CIK 0001992260 · EVP, Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Read SEC document |
| September 23, 2025 Filed Sep 26, 2025 00:01 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $37.87 | $0.00 |
DisclosureSEC source: 0001992260-25-000005 · ownership.xml · derivative · entry 1 Randhawa Simrat · CIK 0001992260 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-09-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after September 23, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:21 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0000950170-25-013485 · ownership.xml · derivative · entry 1 Randhawa Simrat · CIK 0001992260 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:04 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065565 · ownership.xml · derivative · entry 1 Randhawa Simrat · CIK 0001992260 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:43 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000950170-24-007990 · ownership.xml · derivative · entry 1 Randhawa Simrat · CIK 0001992260 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 20:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | PurchaseCommon Stock | 2,000 | $13.20 | $26,400.00 |
DisclosureSEC source: 0000950170-23-049695 · ownership.xml · nonDerivative · entry 2 Randhawa Simrat · CIK 0001992260 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 20:15 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | PurchaseCommon Stock | 2,000 | $13.20 | $26,400.00 |
DisclosureSEC source: 0000950170-23-049695 · ownership.xml · nonDerivative · entry 1 Randhawa Simrat · CIK 0001992260 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.